0001171843-23-006910.txt : 20231109 0001171843-23-006910.hdr.sgml : 20231109 20231109070023 ACCESSION NUMBER: 0001171843-23-006910 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231109 DATE AS OF CHANGE: 20231109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MiNK Therapeutics, Inc. CENTRAL INDEX KEY: 0001840229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40908 FILM NUMBER: 231389973 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 212-994-8250 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: AgenTus Therapeutics, Inc. DATE OF NAME CHANGE: 20210112 8-K 1 f8k_110923.htm FORM 8-K Form 8-K
0001840229 False 0001840229 2023-11-09 2023-11-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  November 9, 2023

_______________________________

MiNK Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware001-4090882-2142067
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

149 Fifth Avenue, Suite 500

New York, New York 10010

(Address of Principal Executive Offices) (Zip Code)

(212) 994-8250

(Registrant's telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.00001 per shareINKTNASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 2.02. Results of Operations and Financial Condition.

On November 9, 2023, MiNK Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2023.  In connection with the announcement, the Company issued a press release, which is being furnished as Exhibit 99.1 to this current report on Form 8-K.

The information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibit

The following exhibit is furnished herewith:

           99.1     Press Release dated November 9, 2023

           104      Cover Page Interactive Data File (embedded within the Inline XBRL document)

 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 MiNK Therapeutics, Inc.
   
  
Date: November 9, 2023By: /s/ Christine M. Klaskin        
  Christine M. Klaskin
  Principal Financial Officer
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

MiNK Therapeutics Reports Third Quarter 2023 Results

  • MiNK presents first-of-a-kind data with allogeneic iNKTs, agenT-797, showing durable clinical benefit in solid tumor cancers and persistence >6 months without toxic pre-conditioning.
  • AgenT-797 demonstrates potential beyond cancer, with improved survival in severe respiratory distress. MiNK plans for expansion in autoimmune and inflammatory diseases.
  • Conference Call on Thursday, November 9, 2023, at 8:30 a.m. ET.

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the third quarter 2023. MiNK executives will host a conference call and webcast at 8:30 a.m. ET to discuss the results and to provide a corporate update.

"This quarter we made important advancements across our iNKT cell platform, including new data that demonstrated the long-term persistence and clinical benefits of iNKTs in heavily pretreated solid tumor cancer patients,” said Dr. Jennifer Buell, President and Chief Executive Officer. “We’ve also progressed our innovative engineered programs, including CARs and TCRs, and made substantial strides expanding our internal cGMP manufacturing, a critical capability to making these novel cells accessible to a broad patient population.”

AgenT-797 has shown promising results in patients with late-stage metastatic cancer, including NSCLC, testicular, appendiceal, and gastric cancers, refractory to traditional therapies. More than 30% of these patients experienced disease stabilization or biomarker responses, and a patient with gastric cancer achieved a durable clinical response. This is especially significant, considering agenT-797’s administration does not require HLA matching or toxic pre-conditioning, setting a new standard in the field of cell therapy.

A randomized phase 2 clinical trial of agenT-797 +/- standard of care chemotherapy +/- Agenus’ botensilimab/balstilimab in patients with 2L gastric cancer is on track to launch this year. The trial will be externally funded and led by Dr. Yelena Janjigian, Chief of Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center.

Financial Results

We ended the third quarter with a cash balance of $6.4 million as compared to $10.6 million at June 30, 2023, and $19.6 million at December 31, 2022. Cash used in operations for the three and nine months ended September 30, 2023, was $4.2 million, and $12.7 million, respectively, compared to $5.6 million and $14.4 million for the same periods in 2022.

Net loss for the nine-months ended September 30, 2023 was $17 million, or $0.50 per share, compared to net loss for the same period in 2022 of $20.2 million or $0.60 per share.

Summary Consolidated Financial Information   
 
Condensed Consolidated Balance Sheet Data   
(in thousands)   
(unaudited)   
                
  September 30, 2023   December 31, 2022         
                
Cash and cash equivalents$6,399  $19,636         
Total assets 7,462   21,472         
                
                
Other Financial Information    
(in thousands)   
(unaudited)   
 Three months ended September 30, Nine months ended September 30,
  2023   2022   2023   2022 
                
Cash used in operations$4,209  $5,615  $12,727  $14,436 
Non-cash operating expenses (income)$993  $(1,989)  2,643  $(348)
                
                
                
Condensed Consolidated Statements of Operations Data   
(in thousands, except per share data)   
(unaudited)   
                
 Three months ended September 30, Nine months ended September 30,
  2023   2022   2023   2022 
                
Operating expenses:               
Research and development 3,427   6,150   12,179   17,303 
General and administrative 1,796   1,838   5,242   5,757 
                
Operating loss 5,223   7,988   17,421   23,060 
                
Other income, net (107)  (1,656)  (422)  (2,838)
                
Net loss$5,116  $6,332  $16,999  $20,222 
                
Per common share data, basic and diluted:               
Net loss$(0.15) $(0.19) $(0.50) $(0.60)
Weighted average number of common shares outstanding, basic and diluted 34,498   33,757   34,293   33,628 
                

Conference Call

United States (New York): 646-968-2525

USA & Canada: 888-596-4144

Conference ID: 8819822

Webcast

A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/uns7ovrj/.

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of agenT-797 and iNKT cells the mechanism of action, potency and safety, interim or top-line data, including statements regarding clinical data of agenT-797 alone and in combination with anti-PD-1, the anticipated benefits of agenT-797 and clinical development plans and timelines. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Investor Contact
917-362-1370
investor@minktherapeutics.com

Media Contact
781-674-4428
communications@minktherapeutics.com

 EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 09, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 09, 2023
Entity File Number 001-40908
Entity Registrant Name MiNK Therapeutics, Inc.
Entity Central Index Key 0001840229
Entity Tax Identification Number 82-2142067
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 149 Fifth Avenue, Suite 500
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10010
City Area Code 212
Local Phone Number 994-8250
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol INKT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 f8k_110923_htm.xml IDEA: XBRL DOCUMENT 0001840229 2023-11-09 2023-11-09 iso4217:USD shares iso4217:USD shares 0001840229 false 8-K 2023-11-09 MiNK Therapeutics, Inc. DE 001-40908 82-2142067 149 Fifth Avenue, Suite 500 New York NY 10010 212 994-8250 false false false false Common Stock, par value $0.00001 per share INKT NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_110923.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "f8k_110923.htm": { "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "dts": { "inline": { "local": [ "f8k_110923.htm" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "gnw-20190101_def.xml" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://globenewswire.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_110923.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Form8K", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "body", "html" ], "reportCount": 1, "baseRef": "f8k_110923.htm", "first": true, "unique": true } } }, "tag": { "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://globenewswire.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001171843-23-006910-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-23-006910-xbrl.zip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